Quantification of Leishmania infantum DNA in the bone marrow, lymph node and spleen of dogs / Quantificação de DNA de Leishmania infantum em medula óssea, linfonodo e baço de cães

The aim of the present study was to quantify the parasite load of Leishmania infantum in dogs using real-time PCR (qPCR). Bone marrow, lymph node and spleen samples were taken from 24 dogs serologically positive for L. infantum that had been put down by the official epidemiological surveillance service. According to the clinical signs the dogs were classified as asymptomatic or symptomatic. After DNA extraction, the samples were subjected to qPCR to detect and quantify L. infantum DNA. Out of the 24 dogs, 12.5% (3/24) were classified as asymptomatic and 87.5% (21/24) as symptomatic. Real-time PCR detected L. infantum DNA in all the animals, in at least one biological sample. In particular, 100% of bone marrow and lymph node scored positive, whereas in spleen, the presence of DNA was detected in 95.9% (23/24). In addition, out of 24 animals, 15 were microscopically positive to amastigote forms of L. infantum in bone marrow. No statistical significant difference was found in the overall mean quantity of DNA among the different biological samples (P = 0.518). Considering each organ separately, there was 100% positivity in bone marrow and lymph nodes, while among the spleen samples, 95.9% (23/24) were positive. Regarding the different clinical groups, the overall mean parasite load varied significantly (P = 0.022). According to the results obtained, it was not possible determine which biological sample was most suitable tissue for the diagnosis, based only on the parasite load. Therefore, other characteristics such as convenience and easily of obtaining samples should be taken into consideration.

O objetivo do presente estudo foi quantificar a carga parasitária de Leishmania infantum em cães pela técnica de PCR em tempo-real (qPCR). Amostras de medula óssea, linfonodo e baço foram obtidos de 24 cães sorologicamente positivos para L. infantum que foram submetidos à eutanásia pelo serviço de vigilância oficial. Segundo os sinais clínicos, os animais foram classificados em assintomáticos ou sintomáticos. Após extração de DNA, as amostras foram submetidas à qPCR para detecção e quantificação de DNA de L. infantum. Dos 24 cães, 12,5% (3/24) foram classificados como assintomáticos e 87,5% (21/24) como sintomáticos. A PCR em tempo real detectou DNA de L. infantum em 100% dos animais, em pelo menos uma amostra biológica. Considerando cada órgão isoladamente, foi observada uma positividade de 100% em medula óssea e linfonodo, já nas amostras de baço 95,9% (23/24) foram positivas. Não foi observada diferença estatística entre a quantidade média geral de DNA entre as diferentes amostras biológicas (P = 0,518). Considerando os diferentes grupos clínicos, a carga parasitária média geral variou significantemente (P = 0,022). De acordo com os resultados obtidos não foi possível eleger a mais apropriada amostra biológica para o diagnóstico, baseado apenas na carga parasitária. Portanto, outras características como a conveniência e a facilidade de obtenção da amostra devem ser consideradas.

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response / Avaliação da fibrose e vascularização do estroma da medula óssea de pacientes com leucemia mielóide crônica tratados com mesilato de imatinibe e sua relação com a resposta citogenética

Chronic Myeloid Leukemia (CML) is a myeloproliferative disease characterized by the presence of the Philadelphia chromosome (translocation between chromosomes 9 and 22), resulting in the formation of the hybrid BCR-ABL protein. Currently, the treatment of CML patients is performed with imatinib mesylate (IM), which promotes the elimination of leukemic cells by inhibiting the kinase activity of BCR-ABL. This study evaluated the effectiveness of IM by monitoring 22 CML patients in a chronic phase treated at the CEPON/SC with IM for a minimum follow-up period of two years. Cytogenetic Response (CR) and bone marrow biopsies (BMB) were evaluated before and after IM treatment. BMB were evaluated by detection of reticulin degree and vascularization. The results were correlated to the CR. Mean time to achieve CR was 9 months and was attained by 77.27 percent of the patients. The results from the initial BMB analysis showed that 59.09 percent presented reticulin of between 2+ and 4+ whereas after treatment, only 27.17 percent presented this degree. With regard to vascularization of the initial sample, 90.91 percent were graded between II and IV, whereas after treatment, 40.91 percent had this degree. The results suggest a positive correlation of degree of reticulin and vascularization with CR.

A Leucemia Mielóide Crônica (LMC) é uma doença mieloproliferativa caracterizada pela presença do cromossomo Filadélfia (translocação entre os cromossomos 9 e 22), que resulta na formação da proteína híbrida BCR-ABL. Atualmente o tratamento de pacientes com LMC é realizado com mesilato de imatinibe (MI), o qual promove a eliminação das células leucêmicas pela inibição da atividade quinase de BCR-ABL. O presente estudo avaliou a eficácia do MI por meio do acompanhamento de pacientes portadores de LMC em fase crônica, atendidos no CEPON/SC tratados com MI pelo tempo mínimo de dois anos. Foram avaliadas a Resposta Citogenética (RC) e as biópsias de medula óssea (BMO) antes e após o tratamento com MI. As BMO foram avaliadas quanto ao grau de reticulina e vascularização. Os resultados correlacionaram-se com a RC cujo tempo médio para obtenção da RC foi de 9 meses, sendo atingida por 77.27 por cento dos pacientes. Na primeira BMO, 59.09 por cento dos pacientes apresentaram grau de reticulina entre 2+ e 4+ e após o tratamento, apenas 27.17 por cento apresentaram esta graduação. Quanto à vascularização da primeira amostra, 90.91 por cento foram graduadas entre II e IV e após o tratamento, 40.91 por cento apresentaram esta graduação. Os resultados sugerem uma correlação diretamente proporcional entre os graus de reticulina e vascularização com a RC.

Avaliação do ciclo celular de células tronco/progenitoras hemopoéticas da medula óssea de camundongos submetidos à desnutrição protéica / Hematopoietic stem/progenitor cell cycle evaluation from bone marrow of malnourished mice

A hemopoese é um processo dinâmico regulado pelo microambiente no qual se situa. O principal tecido hemopoético após o nascimento, a medula óssea, é constituído basicamente por substâncias solúveis, como fatores de crescimento, por uma matriz extracelular (MEC) e por células estromais, além das células hemopoéticas. Esse microambiente indutor íntegro é capaz de regular os processos de sobrevivência, proliferação e diferenciação celular, induzindo a célula a sair de um estado quiescente e entrar em ciclo celular. Contudo, na desnutrição protéica (DP) observa-se redução significativa da celularidade das células hemopoéticas, tanto no compartimento periférico quanto no central, a medula óssea. O comprometimento estrutural do microambinte medular decorrente da desnutrição pode prejudicar a sinalização de indução do ciclo celular, fato este que justificaria o quadro de pancitopenia. Portanto, no presente estudo nos propusemos avaliar o ciclo celular de células tronco/progenitoras hemopoéticas (CTPH) da medula óssea de camundongos desnutridos. Para tanto, utilizamos um modelo murino, sendo a desnutrição induzida a partir de uma ração hipoprotéica. As CTPH foram obtidas por método de depleção imunomagnética e utilizadas para a avaliação do ciclo celular a partir da incorporação de Iodeto de Propídeo (PI) e Laranja de Acridina (AO). Também, foram quantificadas proteínas regulatórias do ciclo celular por western blot e avaliada a expressão de receptores para fibronectina, VLA4 e VLA5. Paralelamente, em modelo ex vivo, avaliou-se a influência de fatores de crescimento e de uma matriz de fibronectina sobre a proliferação das CTPH. Considerando a importância das células estromais na sinalização celular, realizamos o ensaio de CFU-F para a quantificação de células estromais e dos fatores de crescimento secretados. Por fim, avaliamos a eficácia da recuperação nutricional frente às alterações no ciclo celular observadas no modelo de desnutrição...

Hematopoiesis is a dynamic process governed by the microenvironment in witch it is located. Basically, the main hematopoietic tissue, the bone marrow, is composed by soluble factors such growth factors, extracellular matrix (ECM) and stromal cells, besides the hematopoietic cells. This intact inducible microenvironment is capable to control cell survival, proliferation and differentiation, inducing cell to exit a quiescent state and enter the cell cycle. However, in protein malnutrition (PM) is observed a significant reduction of hematopoietic cells, both in peripheral and central compartments. The bone marrow structural impairment due to malnutrition could harm the cell cycle signaling, a fact that could justify the establishment of pancitopenia. Therefore, in this study we set out to assess the cell cycle of hematopoietic stem/progenitors cells (HSPC) from bone marrow of malnourished mice. We used a murine model, and malnutrition induced from a low protein diet. The HPSC were obtained by immunomagnetic depletion method and used for the evaluation of cell cycle from the incorporation of propidium iodide (PI) and Acridine Orange (AO). Also, we quantified the cell cycle regulatory proteins by western blot and evaluated the expression of receptors for fibronectin, VLA4 and VLA5. Meanwhile, in ex vivo model, we evaluated the influence of growth factors and a matrix of fibronectin on the proliferation of HSPC. Considering the importance of stromal cells in cell signaling, we performed the CFU-F assay for the quantification of stromal cells and growth factors secreted. Finally, we evaluated the efficacy of nutritional recovery in the face of cell cycle alterations observed in the model of malnutrition. Briefly, we observed an impairment in the cell cycle of HSPC of undernourished mice, with an increase in this cell population in G0/G1 phase. The proteins that induce cell cycle showed a reduced expression whereas the inhibitory proteins showed increased...

Detección de micrometástasis por RT-PCR de citokeratina 20 y su correlación con la sobrevida global en pacientes portadores de cáncer colorrectal / Cytokeratin 20 as a marker of tumor progression or dissemination in patients with colorectal cancer

Background: Colorectal cancer relapses or metastasizes in 30 percent of cases. Cytokeratin 20 is present in 95 percent of colorectal tumors and their metastases and could be used as a marker to detect tumor cells. Aim: To assess the usefulness and prognostic value of peripheral blood and bone marrow cytokeratin 20 determinations in patients with colorectal cancer. Material and methods: Blood and bone marrow samples were obtained from 56 patients with colorectal cancer aged 26 to 77 years (31 females) before surgical procedure. They were followed for a mean of 22 months (range 2.9 to 72 months) after surgery. Blood and bone marrow from 45 patients without cancer and 35 healthy subjects were used as negative controls. Messenger RNA expression of cytokeratin 20 was studied by real time and nested polymerase chain reaction. Results: Cytokeratin 20 was detected in 6 percent of controls and 41 percent of patients. There was no relation between cytokeratin 20 expression and age, gender, overall survival, tumor relapse, progression, localization or stage. Conclusions: Cytokeratin 20 determination is not useful as a marker of tumor progression or dissemination in patients with colorectal cancer.

Evaluation of iron status: zinc protoporphyrin vis-a-vis bone marrow iron stores.

Zinc protoporphyrin (ZPP) in the red cells is an indicator of iron status in the bone marrow (BM) and can be easily measured by Protofluor-Z Hematofluorometer from Helena Laboratories. It is well known that bone marrow iron is a gold standard for the diagnosis of iron deficiency anemia (IDA) even in the pre-latent phase. Hence, it was considered pertinent to evaluate the diagnostic utility of ZPP in comparison with bone marrow iron stores. 107 random BM were selected over a period of 2(1/2) years; in each case, RBC indices where recorded along with ZPP and Perls' Prussian blue reaction for BM iron stores. The specificity and sensitivity were found to be 77.8% and sensitivity 69.8%, respectively. However, the sensitivity increased up to 96.2% when Hb, RBC indices and ZPP were considered for the diagnosis of IDA.

Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes.

Thirty-five adult myelodysplastic syndrome (MDS) patients were included in this study: 11 refractory anemia (RA), 4 RA with ring sideroblasts (RARS), 9 RA with excess of blasts (RAEB), 10 RAEB in transformation (RAEB-T) and 1 chronic myelomonocytic leukemia (CMML). The ranges of survival were 4-51 months, 40-59 months, 7-38 months, 5-24 months and 5 days, respectively. Three patients died and 3 showed disease progression during the course of the study. A composite analysis of proliferative indices, cytogenetics, immunophenotype and other conventional/novel prognostic parameters in the context of Indian MDS patients was performed. The proliferative indices (AgNOR and Ki 67 positivity), immunophenotypic markers, serum LDH and ferritin levels revealed wide variations and great overlap among different FAB subtypes. The scoring systems (Bournemouth, Dusseldorf and Goasguen) did not correlate with the prognosis and survival (p > 0.05). Clonal cytogenetic abnormalities were detected in 24/35 (68.57%) patients, +8, -5 and -7 being observed commonly. Cytogenetic abnormalities were more frequent in RAEB (88.8%), RAEB-T (80.0%) and RA (63.6%) subtypes of MDS. By Using Mufti's prognostic system and International prognostic scoring system (IPSS), a good positive correlation was found between low risk category and RARS with better survival as compared to other risk categories/FAB subtypes (p < 0.01). However, rest of the FAB subtypes were assigned into high, intermediate and low risk categories without any correlation with the survival and/or leukemic transformation. RARS subtype revealed itself as the better prognostic category according to the cytogenetic findings as well as Mufti's grading system. This was possible due to the longer follow up available for these patients (40-59 months).

Myelodysplastic syndrome and pancytopenia responding to treatment of hyperthyroidism: peripheral blood and bone marrow analysis before and after antihormonal treatment.

Hematological disorders, especially single lineage abnormalities, have been described in hyperthyroidism. Pancytopenia has been reported, without myelodysplastic syndrome or megaloblastic anemia. We studied the peripheral blood smear and the bone marrow aspiration and biopsy of a 65-year-old lady, who presented with pancytopenia and thyrotoxicosis due to multinodular goiter. She denied ingesting any toxic medication. At diagnosis: WBC: 2500/ul, platelets count: 58,000/ul, hemoglobin level: 6.5 g/dl. The bone marrow was moderately hyper cellular with moderate myelofibrosis and arrested hematopoiesis. The TSH level was: 0.02 mIU/l (N: 0.25-4), the fT3: 18 pmol/l (N: 4-10), the routine serum immunologic tests were negative. After treatment with single agent neomercazole (carbimazole), complete recovery of the blood cell counts was obtained within one month. The bone marrow aspiration, performed three months after starting therapy, showed normal hematopoiesis. The thyroid function tests returned to normal and no autoimmune reaction was detected on routine serum testing. Persistent response was observed six months later under medical treatment. The patient has refused surgical treatment. Reversible myelodysplastic syndrome may also be part of the changes in blood picture of patients with hyperthyroidism, probably due to direct toxic mechanism.

Diagnosis of multiple myeloma by demonstration of M protein in bone marrow aspirate by agar gel electrophoresis: a case report.

A number of laboratory tests are used to confirm the diagnosis of multiple myeloma, including M protein in the serum. Since M protein in the serum originate from tumour cells in the bone marrow before circulating in the serum, demonstration of M protein in bone marrow aspirate can be added to the batteries of diagnostic parameters.

Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate

The aim of the present study was to evaluate the impact of a multiple dose regimen of a liposomal formulation of meglumine antimoniate (LMA) on the pharmacokinetics of antimony in the bone marrow of dogs with visceral leishmaniasis and on the ability of LMA to eliminate parasites from this tissue. Dogs naturally infected with Leishmania chagasi received 4 intravenous doses of either LMA (6.5 mg antimony/kg body weight, N = 9), or empty liposomes (at the same lipid dose as LMA, N = 9) at 4-day intervals. A third group of animals was untreated (N = 8). Before each administration and at different times after treatment, bone marrow was obtained and analyzed for antimony level (LMA group) by electrothermal atomic absorption spectrometry, and for the presence of Leishmania parasites (all groups). There was a significant increase of antimony concentration from 0.76 æg/kg wet organ (4 days after the first dose) to 2.07 æg/kg (4 days after the fourth dose) and a half-life of 4 days for antimony elimination from the bone marrow. Treatment with LMA significantly reduced the number of dogs positive for parasites (with at least one amastigote per 1000 host cells) compared to controls (positive dogs 30 days after treatment: 0 of 9 in the LMA group, 3 of 9 in the group treated with empty liposomes and 3 of 8 in the untreated group). However, complete elimination of parasites was not achieved. In conclusion, the present study showed that multiple dose treatment with LMA was effective in improving antimony levels in the bone marrow of dogs with visceral leishmaniasis and in reducing the number of positive animals, even though it was not sufficient to achieve complete elimination of parasites.

Efeitos da lidocaína hiperbárica em concentrações crescentes, administrada no espaço subaracnóideo, sobre a medula e meninges: estudo experimental no cão / Effect of the hyperbaric lidocaína in increasing concentrations, managed in the subaracnóideo space, on the marrow and meninges: experimental study in the dog

Em estudo experimental em ratos, a injeçao de lidocaina subaracnoidea a partir da concentraçao de 7,5 porcento, resultou em mudanças neurofuncionais e histopatologicas. O proposito deste estudo foi investigar, em animais vivos as possiveis alteraçoes clinicas e histologicas desencadeadas por injeçoes de lidocaina hiperbarica nas concentraçoes de 5 porcento, 7,5 porcento e 10 porcento, administradasno espaço subaracnoideo de caes. Quarenta animais foram randomizados em quatro grupos que receberam por via subaracnoidea: G1 glicose a 7,5 porcento e 10 porcento, administradas no espaço subaracnoideo de caes. Quarenta animais foram randomizados em quatro grupos que receberam por via subaracnoidea: G1 glioce a 7,5 porcento, G2 lidocaina hiperbarica a 5 porcento, G3 lidocaina hiperbarica a 7,5porcento e G4 lidocaina hiperbarica a 10 porcento. A punçao subaracnoidea foi realizada no espaço intervetebral L6-L7. O volume da solução injetada foi de 1 ml. Os animais foram sacrificados apos sete dias de observaçao em cativeiro.As porçoes lombar e sacral da medula foram removidas para exame histologico, por microscopia optica. Os caes pertencentes aos grupos G1 e G2, ao apresentaram alteraçoes clinicas e histologicas na medula e meninges. Foi observado tres casos em G3, de necrose em focosno tecido medular mas, necrose abrangendo toda a superficie da medula em somente um dos animais e, a despeito dos achados histologicos, um destes caes permaneceu clinicamente normal. No G4, sete caes apresentaram alteraçoes clinicas e histologicas. As mudanças histologicas encontradas variaram de areas de necrose restritas a algumas regioes da medula a necrose em faixa abrangendo toda a superficie medular. Observamos diminuiçao de força muscular nas patas posteriores em seis animais, sendo que em tres deles houve associação em relaxamento de esfincter anal, e em um dos animais, a diminiçao do tonus esfincteriano foi a unica alteraçao clinica obervada. A neurotoxicidade da lidocaina hiperbarica espinhal em concentraçoes supra-clinicas determinou alteraçoes histopatologicas, restritas ao tecido nervoso da medula espinhal. A extensão e gravidade das lesoes foram intimamente relacionadas com a concentração da lidocaina. Lesoes brandas causadas por concentraçoes mais baixas de lidocaina podem nao manifestar alteraçoes clinicas.

Detección de micrometástasis en médula ósea de pacientes con cáncer de vesícula biliar / Detection of bone marrow micrometastases in patients with gallbladder cancer

Background: There is a very strong documented correlation between the appearance of cancer cells in blood and occurrence of metastasis in gastrointestinal cancer. Aim: To determine MUC1, CK19, CK20 and CEA mRNA expression in bone marrow of patients with gallbladder cancer and evaluate its clinical significance. Material and methods: Sixty eight samples were analyzed, 38 bone marrow samples of gallbladder cancer patients, 20 healthy donors, and 10 frozen samples of gallbladder cancer. Nested reverse transcriptase-polymerase chain reaction (nested RT-PCR) was used to analyze mRNA expression. Results: All frozen tumors were positive for CEA, CK19, and MUC1 mRNA and 70 percent were positive for CK20. Seventeen of 20 donor samples were positive for MUC1 and only one sample from donors was positive for both CK20 and CK19 mRNA. Among the 38 blood and bone marrow samples of gallbladder cancer patients, the expression of MUC1, CK19, CK20, and CEA, mRNA was 60.5 percent (23/38), 31.6 percent (12/38), 7.9 percent (3/38), and 7.9 percent (3/38), respectively. Disregarding the MUC1 results. 37 percent (14/38), 13 percent (5/38) and 5 percent (2/38) were positive for one, two and three markers respectively. Not significant differences were found in survival with a follow up to 12 months. Conclusion: Our results indicate that the molecular detection of tumor cells in bone marrow in patients with gallbladder carcinoma is technically possible, being CEA, CK19 and CK20 gene expression the best markers. The MUC1 gene expression marker was highly unspecific and it should not been considered. The detection of bone marrow micrometastasis might be helpful in prognosis and the selection of clinical treatment but a larger series with a longer follow-up should be studied.

Titanium pigment in tissues of drug addicts: report of 5 necropsied cases

O objetivo deste relato é descrever os achados anatomopatológicos de cinco casos de toxicômanos com pigmento de titânio em vários órgãos, após injeção de comprimidos esmagados de cloridrato de propoxifeno. Foram obtidos fragmentos do fígado, baço, pulmões, linfonodos e medula óssea e, após a avaliação macroscópica, amostras foram submetidas à microscopia de luz comum e de luz polarizada. Em todos os cinco casos, foi encontrado um pigmento com características de dióxido de titânio nas amostras dos órgãos estudados. Nossos achados sugerem que a pesquisa sobre pigmento de titânio em tecidos corporais deva ser complementada, considerando-se a contribuição de dados morfológicos em Patologia Forense.

WR2721 (amifostina) e radioproteçäo da medula óssea / WR2721 (amifostina) and bone marrow radioprotection

A medula óssea é bastante radiosensível e dependendo da intensidade, suas alteraçöes podem causar a morte de indivíduos expostos, pela Síndrome Aguda da Radiaçäo.Constitui-se também num tecido crítico para a interaçäo de drogas e radiaçäo, durante o tratamento de doenças malignas, às vezes, limitando tais procedimentos. No presente artigo säo abordadas as características do radioprotetor amifostina e seu papel na proteçäo da medula óssea irradiada.

Anti-implantation effect of a bone-marrow cytokine-BIM.

Successful implantation of blastocyst is dependent upon a cytokine induced localized immunosuppression at uterus. BIM, a bone marrow secreted bio-immunomodulator (BIM) has been observed to have positive immunomodulatory activity in immunosuppressed cases. As pregnancy is associated with immunosuppression upregulation of the suppressed immune system by injection of BIM (conc. 0.08 microg/g b.wt once in rats b.wt. <150 gm or 0.2 microg/g b.wt thrice in rats weighing > 160 gm) is believed to prevent implantation. The anti-implantation action of BIM is probably mediated via mononuclear cells at site of uterus, the effect is reversible and a single dose did not affect the estrous cycle. Multiple dose of BIM however, produce prolonged diestrous and this is probably an autonomic phenomena.

Hairy cell leukemia: a histo-cytochemical and ultra-structural study

We studied five patients with hairy cell leukemia (HCL) diagnosed within the last ten years at the Department of Hematology of Universidade Federal de Sao Paulo - Escola Paulista de Medicina. Our purpose was to analyze the value of transmission electron microscopy (TEM) by comparing this method with the conventional ones. At diagnosis, patients presented weight loss, spleen enlargement and hairy cells (HC) in peripheral blood and bone marrow slides. HC was characterized by morphology and tartrate test resistance in the acid phosphatase reaction (TRAP). At the evaluation time, the amount of HC ranged from 1 per cent to 85 per cent of WBC count. All patients, except two, had phenotype B. In these last two, TRAP as well as phenotype B could not be documented due to low HC numbers in their exams. Cytoplasmatic projections and the absecence of lamellar ribosomic complex were the most frequent ultrastructural findings, even in those patients with the lowest HC numbers. Based on these features, TEM is an efficient method for searching for HC at HCL diagnosis and during the course of the disease.

Anaemia in diabetes mellitus

Eighty five patients with diabetes mellitus and 25 normal controls were studied clinically together with evaluation of their red cell values, bone marrow picture, serum iron and liver function tests. Normochromic normocytic anaemia was found to be a characterstic feature of diabetics having chronic complications or infections. Macrocytic normochromic anaemia was present in diabetics having ketoacidosis. Possible underlying mechanisms for the present anaemia was discussed. In non complicated diabetics anaemia was not present and serum iron was within normal limits. Conclusion was reached that the presence of anaemia in a diabetic patient is a sign of diabetic complications